Research ArticleNuclear Oncology
Technetium-99m-Labeled HL91 to Identify Tumor Hypoxia: Correlation with Fluorine-18-FDG
Gary J.R. Cook, Stephen Houston, Sally F. Barrington and Ignac Fogelman
Journal of Nuclear Medicine January 1998, 39 (1) 99-103;
Gary J.R. Cook
Stephen Houston
Sally F. Barrington


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Technetium-99m-Labeled HL91 to Identify Tumor Hypoxia: Correlation with Fluorine-18-FDG
Gary J.R. Cook, Stephen Houston, Sally F. Barrington, Ignac Fogelman
Journal of Nuclear Medicine Jan 1998, 39 (1) 99-103;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
- Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET
- Oncological molecular imaging: nuclear medicine techniques
- Delineation of Hypoxia in Canine Myocardium Using PET and Copper(II)-Diacetyl-bis(N4-Methylthiosemicarbazone)
- Scintigraphic Imaging of the Hypoxia Marker 99mTechnetium-labeled 2,2''-(1,4-Diaminobutane)bis(2-methyl-3-butanone) Dioxime (99mTc-labeled HL-91; Prognox): Noninvasive Detection of Tumor Response to the Antivascular Agent 5,6-Dimethylxanthenone-4-acetic Acid